Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061511 | 0.88 | ALOX5AP (0.36) | SCARB1GRIN1GRIN2BPTGS2KDM4E | |
| SCHEMBL3070337 | 0.81 | TP53 (0.33) | SCARB1GRIN1GRIN2BPTGS2 | |
| SCHEMBL5624309 | 0.80 | TP53 (0.32) | — | |
| SCHEMBL3060465 | 0.79 | GUSB (0.37) | GRIN1GRIN2BPTGS2ALDH1A1HDAC6 | |
| SCHEMBL3066093 | 0.79 | ALDH1A1 (0.40) | GRIN1GRIN2BPTGS2KDM4EUSP2 | |
| SCHEMBL3065442 | 0.77 | AGTR1 (0.39) | GRIN1GRIN2BKDM4EALDH1A1TSHR | |
| SCHEMBL3070814 | 0.77 | APP (0.34) | GRIN1GRIN2B | |
| SCHEMBL3064978 | 0.75 | MAPT (0.37) | KDM4EUSP2ALDH1A1TSHRXBP1 | |
| SCHEMBL3054928 | 0.73 | TP53 (0.41) | GRIN1GRIN2BALDH1A1NPSR1 | |
| SCHEMBL13089666 | 0.73 | DYRK1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | SCARB1 1758/4885GRIN1 231/4885GRIN2B 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.